Skip to content

Skeletal Metastasis Registry

The International Skeletal Metastasis Registry

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05058014
Enrollment
50
Registered
2021-09-27
Start date
2018-08-16
Completion date
2023-12-06
Last updated
2024-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Bone Tumor

Keywords

Biopsy-proven or clinically-obvious metastatic bone disease

Brief summary

This is a prospective, observational study designed to contribute data from patients with symptomatic metastatic bone disease treated at Sibley Memorial Hospital and Johns Hopkins Medicine to an international registry hosted by the Swedish Regional Cancer Centrum in Stockholm, Sweden. This protocol supports a worldwide effort to collect and store information from patients treated for symptomatic bone metastases within the International Skeletal Metastasis Registry (ISMR)

Detailed description

The registry is designed to update a suite of clinical decision-support tools designed for use when treating patients with metastatic bone disease. The models estimate the likelihood of survival at 1, 3, 6, 12, 18, and 24 months post surgery, which in turn, may be used for surgical decision-making.

Interventions

None listed

Sponsors

Murtha Cancer Center
CollaboratorUNKNOWN
Defense Health Programs with the U.S. Army Medical Research and Materiel Command
CollaboratorUNKNOWN
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients, age 22 or older * Biopsy-proven or clinically-obvious metastatic bone disease * Symptomatic bone lesion requiring intervention o Including, not limited to, radiotherapy, cryotherapy, radiofrequency ablation, operative fixation, prosthetic replacement, amputation, or any combination of the above.

Design outcomes

Primary

MeasureTime frameDescription
Overall survival (OS)Up to 24 Months post surgeryOS (in months) calculated from the date of intervention.

Secondary

MeasureTime frameDescription
Reoperation or retreatment for any reasonUp to 24 24 months post surgeryNumber of participants with reoperation or retreatment for any reason.
Time to reoperation or retreatment for any reasonUp to 24 months post surgeryTiming of reoperation calculated from the date of intervention.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026